Cellectar Presents Data from DLBCL Cohort of its Phase 2 CLOVER-1 Study at the European Society for Medical Oncology (ESMO) Congress Sep 30, 2019
Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Multiple Myeloma Sep 24, 2019
Cellectar Presents Data from Cohort 6 of its CLR 131 Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma Sep 16, 2019
Cellectar Announces Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2019 Sep 10, 2019
Cellectar Announces Late-Breaker Poster Presentation at the 17th International Myeloma Workshop Sep 4, 2019
CLR 131 Advances to Second Malignant Brain Tumor Cohort of Ongoing Pediatric Phase 1 Study Aug 14, 2019
Cellectar Receives FDA Fast Track Designation for CLR 131 in Diffuse Large B-Cell Lymphoma Jul 9, 2019